Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q53H82
UPID:
LACB2_HUMAN
Alternative names:
Beta-lactamase-like protein 2
Alternative UPACC:
Q53H82; A8K2D6; Q9Y392
Background:
Endoribonuclease LACTB2, also known as Beta-lactamase-like protein 2, plays a crucial role in RNA processing by preferentially cleaving 3' to purine-pyrimidine dinucleotide motifs in single-stranded RNA. This specific cleavage is vital for maintaining normal mitochondrial function and ensuring cell viability, highlighting its fundamental role in cellular metabolism.
Therapeutic significance:
Understanding the role of Endoribonuclease LACTB2 could open doors to potential therapeutic strategies. Its essential function in RNA processing and mitochondrial health positions it as a key target for interventions aimed at enhancing cellular resilience and treating mitochondrial disorders.